Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer [PDF]
Cancers, 2021 Non-steroidal anti-androgens have a major role in the treatment of non-localized prostate cancer. Interleukins are involved in the regulation of many cellular functions in prostate cancer and also modify cellular response to anti-androgens. A specific role of selected IL is presented in this review.
Culig Z.
openaire +3 more sources
Virtual Screening and Bioactivity Evaluation of Novel Androgen Receptor Antagonists From Anti-PCa Traditional Chinese Medicine Prescriptions [PDF]
Frontiers in Chemistry, 2020 Prostate cancer (PCa), a type of malignancy that arises in the prostate gland, is the most commonly diagnosed neoplasm and the second leading cause of cancer-related deaths in men.
Wenya Han +6 more
doaj +2 more sources
Second generation androgen receptor antagonists and challenges in prostate cancer treatment [PDF]
Cell Death and Disease, 2022 Prostate cancer is a hormone-dependent malignancy, whose onset and progression are closely related to the activity of the androgen receptor (AR) signaling pathway.
Yanhua Chen +4 more
doaj +2 more sources
Identifying androgen receptor antagonists using a metabolically competent high-throughput screening assay [PDF]
Current Research in ToxicologyAndrogen receptor (AR) is a nuclear receptor with a well-established role in sexual function and development. Modifications in AR can lead to endocrine disruption, cancer, and other diseases, making it imperative to identify compounds that influence ...
Caitlin Lynch +5 more
doaj +2 more sources
Intracranial Assessment of Androgen Receptor Antagonists in Mice Bearing Human Glioblastoma Implants [PDF]
Int J Mol Sci, 2023 The median survival time of patients with an aggressive brain tumor, glioblastoma, is still poor due to ineffective treatment. The discovery of androgen receptor (AR) expression in 56% of cases offers a potential breakthrough.
Nomi Zalcman +5 more
core +2 more sources
Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists [PDF]
Frontiers in Pharmacology, 2018 Androgen receptor (AR), an important target in the current androgen derivation therapy, plays a critical role in the development and progress of prostate cancer (PCa).
Lingyan Wang +3 more
doaj +2 more sources
Metabolism-Guided Selective Androgen Receptor Antagonists: Design, Synthesis, and Biological Evaluation for Activity against Enzalutamide-Resistant Prostate Cancer [PDF]
J Med Chem, 2023 A major challenge for new drug discovery in the area of androgen receptor (AR) antagonists lies in predicting the druggable properties that will enable small molecules to retain their potency and stability during further studies in vitro and in vivo ...
Duane D. Miller (238777) +6 more
core +2 more sources
Screening for insulin-independent pathways that modulate glucose homeostasis identifies androgen receptor antagonists [PDF]
eLife, 2018 Pathways modulating glucose homeostasis independently of insulin would open new avenues to combat insulin resistance and diabetes. Here, we report the establishment, characterization, and use of a vertebrate ‘insulin-free’ model to identify insulin ...
Sri Teja Mullapudi +10 more
doaj +2 more sources
The protein composition of exosomes released by prostate cancer cells is distinctly regulated by androgen receptor-antagonists and -agonist to stimulate growth of target cells [PDF]
Cell Communication and SignalingBackground Prostate cancer (PCa) is a prevalent malignancy in men worldwide, ranking as the second leading cause of cancer-related death in Western countries. Various PCa hormone therapies, such as androgen receptor (AR)-antagonists or supraphysiological
Golnaz Atri Roozbahani +4 more
doaj +2 more sources
Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer [PDF]
The Cancer Journal, 2013 Persistent androgen receptor (AR) signaling despite low levels of serum androgens has been identified as a critical target for drug discovery in castration-resistant prostate cancer (CRPC). As proof of principle that the AR remains relevant in CRPC, 2 AR-targeted agents recently approved by the Food and Drug Administration-abiraterone and enzalutamide ...
Dana, Rathkopf, Howard I, Scher
openaire +3 more sources